Nektar Therapeutics

NKTR
Delayed Nasdaq - 09/20 10:00:00 pm
20.15USD
-0.35%
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Sales 1 193 106
EBITDA 699 -496
Operating profit (EBIT) 688 -505
Pre-Tax Profit (EBT) 683 -511
Net income 681 -504
P/E ratio 8,70x -6,99x
EPS ( $ ) 3,78 -2,88
Dividend per Share ( $ ) - -
Yield - -
Reference price ( $ ) 32,870 20,150
Announcement Date 02/28/2019
09:10pm
-
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 2018 2019 (e)
Debt 52,5 129
Finance - -
Operating income (EBITDA) 699 -496
Leverage
(Debt/EBITDA)
0,08x -
Capital Expenditure 11,6 12,2
Free Cash Flow (FCF) 707 -487
Book Value Per Share (BVPS) ( $ ) 9,90 7,75
Cash Flow per Share (  ) - -
Announcement Date 02/28/2019
09:10pm
-
Balance Sheet Analysis
Financial Ratios
Size 2019e 2020e
Capitalization 3 532 M $ -
Entreprise Value (EV) 3 661 M $ 3 148 M $
Valuation 2019e 2020e
P/E ratio (Price / EPS) -6,99x -7,06x
Capitalization / Revenue 33,3x 18,6x
EV / Revenue 34,5x 19,3x
EV / EBITDA -7,39x -7,23x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 2,60x 3,75x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -476% -251%
Operating Leverage (Delta EBIT / Delta Sales) -1,90x 0,07x
Net Margin (Net Profit / Revenue) -475% -269%
ROA (Net Profit / Asset) -26,5% -34,7%
ROE (Net Profit / Equities) -35,4% -35,8%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   11,5% 7,11%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) 18,0x 7,74x
Financial Leverage (Net Debt / EBITDA) -0,26x -
Price Earning Ratio
BNA & Dividende